Fatima M. Izhaeva

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet · 2021 · 1.8K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova et al. · The Lancet · 2020 · 1.1K citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults

Amir I. Tukhvatulin, Inna V. Dolzhikova, Dmitry V. Shcheblyakov et al. · The Lancet Regional Health - Europe · 2021 · 71 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow

Inna V. Dolzhikova, Vladimir А. Gushchin, Dmitry V. Shcheblyakov et al. · medRxiv · 2021 · 17 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +17

Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study

Amir I. Tukhvatulin, Inna V. Dolzhikova, Alina S. Dzharullaeva et al. · Frontiers in Immunology · 2023 · 17 citations · Full text

Veterinary Medicine, Infectious Diseases, Pediatrics +17